The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2, open-label, dose-escalation, dose-expansion study of menin inhibitor DSP-5336 in adult patients with acute leukemia with and without mixed-lineage leukemia (MLL)-rearrangement (r) or nucleophosmin 1 (NPM1) mutation (m).
 
Naval Guastad Daver
Consulting or Advisory Role - Abbvie; Agios; Amgen; Arog; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; Gilead Sciences; Immunogen; Jazz Pharmaceuticals; Novartis; Pfizer; SERVIER; Shattuck Labs; Syndax; Trillium Therapeutics
Research Funding - Abbvie; Amgen; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo; FATE Therapeutics; Genentech; Gilead Sciences; Glycomimetics; Hanmi; Immunogen; Novimmune; Pfizer; Servier; Trillium Therapeutics; Trovagene
 
John Affinito
Employment - Sumitomo Dainippon Pharma
 
Hongliang Cai
Employment - Sumitomo Dainippon Pharma
 
Hanna Dobrowolska
Employment - Sumitomo Dainippon Pharma
 
Ken Eguchi
Employment - Sumitomo Dainippon Pharma
 
Zijing Zhang
Employment - Sumitomo Dainippon Pharma
 
Jay Stoudemire
Employment - Sumitomo Dainippon Pharma
 
Akinobu Watanabe
Employment - Sumitomo Dainippon Pharma
 
Pablo Martinez
Employment - Sumitomo Dainippon Pharma
 
Philip Komarnitsky
Employment - Sumitomo Dainippon Pharma